Company: DARE
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001401914-25-000050
Chunk: 111

Company: Dare Bioscience, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 2
Chunk 111
---
 ended September 30, 2025 as compared to the three months ended September 30, 2024 was primarily due to an increase on interest earned on cash balances in the current period. 

Comparison of Nine Months Ended September 30, 2025 and 2024 (Unaudited)

The following table summarizes our condensed consolidated results of operations for the periods indicated, together with the changes in those items in terms of dollars and percentage:

Nine Months Ended September 30,Change20252024$%Revenues:Royalty revenue$6,517 $73,431 $(66,914)(91)%Total revenue6,517 73,431 (66,914)(91)%Operating expenses:General and administrative 7,186,272 7,159,979 26,293 — %Research and development 4,901,311 10,969,066 (6,067,755)(55)%Royalty expense— 7,674 (7,674)(100)%Total operating expenses12,087,583 18,136,719 (6,049,136)(33)%Loss from operations(12,081,066)(18,063,288)5,982,222 (33)%Other income (expense)Sale of royalty and milestone rights, net— 20,379,376 (20,379,376)(100)%Other income (expense), net123,510 (863,289)986,799 (114)%Net (loss) income$(11,957,556)$1,452,799 $(13,410,355)(923)%Other comprehensive (loss) income:Foreign currency translation adjustments32,843 (1,729)34,572 (2000)%Comprehensive (loss) income$(11,924,713)$1,451,070 $(13,375,783)(922)%

Revenues

Revenues for the nine months ended September 30, 2025 and September 30, 2024 are related to our license agreement with Organon to commercialize XACIATO. From and after April 1, 2024, any revenue we recognize under such license agreement will be recognized as non-cash royalty revenue. See "—Financial Overview—Revenue," above for information. 

General and administrative expenses

For each of the nine months ended September 30, 2025 and 2024, G&A expenses were approximately $7.2